http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Ahmed Abu-Zaid,Osama Alomar,Nora F AlNaim,Fatimah Shakir Abualsaud,Mohammed Ziad Jamjoom,Latifa F AlNaim,Abdullah AMA Almubarki,Saeed Baradwan,Saud Abdullah Saud Aboudi,Faisal Khalid Idris,Meshael Fod 대한산부인과학회 2022 Obstetrics & Gynecology Science Vol.65 No.2
We aimed to perform a systematic review and meta-analysis of all randomized placebo-controlled trials (RCTs)that examined the analgesic benefits of preemptive pregabalin among patients undergoing minimally invasivehysterectomy. Five major databases were systematically screened from inception until August 29, 2021 Relevantstudies were evaluated for risk of bias. Endpoints were analyzed using the random-effects model and pooled asthe mean difference or risk ratio with a 95% confidence interval. Four studies with seven treatment arms met theinclusion criteria. The total sample size was 304 patients: 193 and 111 patients were allocated to the pregabalin andplacebo groups, respectively. Overall, the included studies revealed a low risk of bias. The summary results revealedthat the mean postoperative pain scores at rest were significantly lower in the pregabalin group than in the controlgroup at 0, 2, 4, 6, 12, and 24 hours. Moreover, the mean postoperative pain scores on movement/coughing weresignificantly lower in the pregabalin group than in the control group at 12 and 24 hours. The rate of patients whowere opioid-free postoperatively was significantly higher in the pregabalin group than in the control group. Therewas no significant difference between the groups in terms of the mean postoperative time to first rescue analgesicand the rates of adverse events. Compared with placebo, preemptive pregabalin was largely safe, and was correlatedwith superior analgesic effects in terms of lower postoperative pain scores and higher opioid-sparing effects. Additional RCTs are needed to confirm these findings.
Ahmed Abu-Zaid,Saeed Baradwan,Ibtihal Abdulaziz Bukhari,Abdullah Alyousef,Mohammed Abuzaid,Saleh A. K. Saleh,Heba M. Adly,Osama Alomar,Ismail Abdulrahman Al-Badawi 대한산부인과학회 2024 Obstetrics & Gynecology Science Vol.67 No.1
This systematic review and meta-analysis aimed to examine the effect of the antioxidant alpha-lipoic acid (ALA) on various cardiometabolic risk factors and hormonal parameters in patients with polycystic ovary syndrome (PCOS). We searched PubMed, EMBASE, SCOPUS, Cochrane Library, and Web of Science databases without language restrictions until May 2023 to find randomized controlled trials (RCTs) that assessed the impact of ALA supplementation on anthropometric, glycemic, lipid, oxidative stress, and hormonal parameters in women with PCOS. Outcomes were summarized using the standardized mean difference (SMD) and 95% confidence interval (CI) in a random-effects model. An I2 statistic of >60% established significant between-study heterogeneity. The overall certainty of the evidence for each outcome was determined using the grading of recommendations, assessment, development, and evaluations system. Seven RCTs met the inclusion criteria. The ALA group had significant reductions in fasting blood sugar (fasting blood sugar (FBS), n=7 RCTs, SMD, -0.60; 95% CI, -1.10 to -0.10; I2=63.54%, moderate certainty of evidence) and homeostatic model assessment for insulin resistance (homeostatic model assessment of insulin resistance (HOMA-IR), n=4 RCTs, SMD, -2.03; 95% CI, -3.85 to -0.20; I2=96.32%, low certainty of evidence) compared with the control group. However, significant differences were observed between the groups in body mass index, insulin, estrogen, follicle-stimulating hormone, luteinizing hormone, testosterone, low-density lipoprotein, highdensity lipoprotein, triglyceride, total cholesterol, malondialdehyde, or total antioxidant capacity profiles. ALA supplementation improves FBS and HOMA-IR levels in women with PCOS. ALA consumption is an effective complementary therapy for the management of women with PCOS.